基于患者源性口腔鳞状细胞癌类器官的药敏分析与初步临床应用

doi:10.13701/j.cnki.kqyxyj.2024.08.010

口腔医学研究 ›› 2024, Vol. 40 ›› Issue (8): 715-721.DOI: 10.13701/j.cnki.kqyxyj.2024.08.010

基于患者源性口腔鳞状细胞癌类器官的药敏分析与初步临床应用

陈霖^1,2,3, 陈寅瑜^1,2,3, 李欣然^1,2,3, 葛良玉^1,3, 王守鹏^1,3, 孟箭^1,2,3*

1.徐州医科大学徐州临床学院江苏徐州 221000;
2.徐州市中心医院口腔科江苏徐州 221000;
3.徐州医科大学口腔医学院江苏徐州 221000

收稿日期:2024-01-03 出版日期:2024-08-28 发布日期:2024-08-22
通讯作者: *孟箭,E-mail:mrocket@126.com
作者简介:陈霖(1997~ ),男,江苏徐州人,硕士在读,主要从事口腔颌面外科相关研究。
基金资助:
国家口腔疾病临床医学研究中心开放课题(编号:NCRCO-202101);徐州医科大学附属医院发展基金项目(编号:XYFY202207)

Drug Sensitivity Analysis and Preliminary Clinical Application Based on Patient-derived Organoid in Oral Squamous Cell Carcinoma

CHEN Lin^1,2,3, CHEN Yinyu^1,2,3, LI Xinran^1,2,3, GE Liangyu^1,3, WANG Shoupeng^1,3, MENG Jian^1,2,3*

1. Xuzhou Clinical College of Xuzhou Medical University, Xuzhou 221000, China;
2. Department of Stomatology, Xuzhou Central Hospital, Xuzhou 221000, China;
3. School of Stomatology, Xuzhou Medical University, Xuzhou 221000, China

Received:2024-01-03 Online:2024-08-28 Published:2024-08-22

摘要/Abstract

摘要： 目的: 基于所建立的患者源性口腔鳞状细胞癌类器官模型进行药物敏感性实验,对相应患者制定个性化药物治疗方案,观察其疗效与实验结果的匹配性。方法: 本研究将通过活检或根治手术获得新鲜口腔鳞状细胞癌标本建立患者源性类器官模型,依托此模型对6种治疗口腔鳞状细胞癌药物(顺铂、紫杉醇、5-FU、西妥昔单抗、阿培利司、Nutlin-3)的敏感性进行测定,并对其中4例活检患者参考实验结果制定个性化用药方案,观察两个疗程后的近期治疗效果。结果: 本研究成功建立了10例OSCC类器官(成功率10/12,83.3%),均可稳定传代、扩增达4代以上,且与亲本肿瘤组织表现出高度一致的组织病理学特征。口腔鳞状细胞癌类器官模型在药敏实验结果中表现出个体化差异,4例接受药物治疗的患者肿瘤控制结果均达到部分缓解标准,与实验结果一致。结论: 本实验建立的患者源性口腔鳞状细胞癌类器官模型高度还原了同源亲本肿瘤的组织病理学特点,基于该模型的体外药敏实验与相应患者临床治疗反应一致,为建立个性化口腔鳞状细胞癌精准药物治疗新体系奠定基础。

关键词: 患者源性类器官, 口腔鳞状细胞癌, 体外药敏实验, 精准治疗, 临床转化

Abstract: Objective: To perform drug sensitivity experiments on patient-derived oral squamous cell carcinoma (OSCC) organoid models and to design individualized drug therapies for the corresponding patients. Mehthods: In the present study, patient-derived organoid (PDO) models were established by obtaining fresh specimens through biopsy or radical operation. These models were used to determine the sensitivity of six drugs (cisplatin, paclitaxel, 5-FU, Cetuximab, Alpelisib, and Nutlin-3) to OSCC. Four of the biopsy patients were given individualized medication according to the experimental results and the short-term therapeutic effect was observed after two courses of treatment. Results: Ten OSCC organoids were successfully established (success rate=10/12, 83.3%) , which could be stably passaged and amplified for more than four generations. The histopathology characteristics of OSCC were highly consistent with those of their parental tumor tissues. The PDO models derived from different patients showed individual differences in the results of drug sensitivity tests. The tumor control results of 4 biopsy patients all met the partial remission criteria, which were consistent with the experimental results. Conclusion: The histopathological characteristics of the established OSCC PDO models were highly similar to those of their parental tumors. The results of the in vitro drug sensitivity tests based on these models were consistent with the clinical treatment response of the corresponding patients, laying a foundation for the establishment of a new individualized and precise drug treatment system for OSCC.

Key words: patient-derived organoid, oral squamous cell carcinoma, in vitro drug sensitivity test, precision therapy, clinical translation

陈霖, 陈寅瑜, 李欣然, 葛良玉, 王守鹏, 孟箭. 基于患者源性口腔鳞状细胞癌类器官的药敏分析与初步临床应用[J]. 口腔医学研究, 2024, 40(8): 715-721.

CHEN Lin, CHEN Yinyu, LI Xinran, GE Liangyu, WANG Shoupeng, MENG Jian. Drug Sensitivity Analysis and Preliminary Clinical Application Based on Patient-derived Organoid in Oral Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2024, 40(8): 715-721.

参考文献

[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33.
[2] 赵国发,王晓芳,张蕾,等. 药物疗法在头颈部鳞癌治疗中的应用研究进展[J]. 山东医药,2021,61(9):110-115.
[3] 孙树洋,张志愿.基于肿瘤临床前模型建立头颈癌新型药物基因组学的必要性及展望[J].山东大学学报(医学版),2021,59(9):57-63.
[4] Jacob F, Salinas RD, Zhang DY, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity [J]. Cell, 2020, 180(1):188-204.e22.
[5] Driehuis E, Kretzschmar K, Clevers H, et al. Establishment of patient-derived cancer organoids for drug-screening applications [J]. Nat Protoc, 2020, 15(10):3380-3409.
[6] 类器官药物敏感性检测指导肿瘤精准治疗临床应用专家共识(2022年版)编写专家组.类器官药物敏感性检测指导肿瘤精准治疗临床应用专家共识(2022年版)[J].中国癌症防治杂志,2022,14(3):234-239.
[7] Chow LQM. Head and neck cancer [J]. N Engl J Med, 2020, 382(1):60-72.
[8] Kaidar-Person O, Gil Z, Billan S. Precision medicine in head and neck cancer [J]. Drug Resist Updat, 2018, 40:13-16.
[9] Karakasheva TA, Kijima T, Shimonosono M, et al. Generation and characterization of patient-derived head and neck, oral, and esophageal cancer organoids [J]. Curr Protoc Stem Cell Biol, 2020, 53(1):e109.
[10] Wang HM, Zhang CY, Peng KC, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study [J]. Cell Rep Med, 2023, 4(2):100911.
[11] Driehuis E, Kolders S, Spelier S, et al. Oral mucosal organoids as a potential platform for personalized cancer therapy [J]. Cancer Discov, 2019, 9(7):852-871.
[12] Nair S, Bonner JA, Bredel M. EGFR mutations in head and neck squamous cell carcinoma [J]. Int J Mol Sci, 2022, 23(7):3818.
[13] Vitale I, Shema E, Loi S, et al. Intratumoral heterogeneity in cancer progression and response to immunotherapy [J]. Nat Med, 2021, 27(2):212-224.
[14] LeSavage BL, Suhar RA, Broguiere N, et al. Next-generation cancer organoids [J]. Nat Mater, 2022, 21(2):143-159.
[15] 胡勤刚,赵星星.口腔鳞状细胞癌肿瘤相关成纤维细胞的研究进展[J].口腔医学研究,2020,36(4):309-313.
[16] Wakamatsu T, Ogawa H, Yoshida K, et al. Establishment of organoids from human epithelioid sarcoma with the air-liquid interface organoid cultures [J]. Front Oncol, 2022, 12:893592.
[17] Parikh AS, Yu VX, Flashner S, et al. Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer [J]. Oral Oncol, 2023, 138:106330.
[18] Kim SC, Park JW, Seo HY, et al. Multifocal organoid capturing of colon cancer reveals pervasive intratumoral heterogenous drug responses [J]. Adv Sci (Weinh), 2022, 9(5):e2103360.

基于患者源性口腔鳞状细胞癌类器官的药敏分析与初步临床应用

Drug Sensitivity Analysis and Preliminary Clinical Application Based on Patient-derived Organoid in Oral Squamous Cell Carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	刘家琦, 梁登桓, 张佳佳, 郭超杰, 刘昱词, 徐江, 曾妍, 郑军. COL7A1和LAMC2在口腔鳞状细胞癌中的表达及预后意义[J]. 口腔医学研究, 2024, 40(7): 634-639.
[2]	庞晓婵, 陈青立, 雒国凤, 尚政军. 牙龈卟啉单胞菌对口腔鳞状细胞癌化疗耐药行为的影响[J]. 口腔医学研究, 2024, 40(5): 413-416.
[3]	付凯钰, 常云汉, 史恩宇, 史澍睿. 共载吲哚菁绿和Nrf2-siRNA的多功能纳米粒子对抗口腔鳞状细胞癌的体外作用研究[J]. 口腔医学研究, 2024, 40(5): 422-428.
[4]	陈嘉雯, 丁啸, 栾可峰, 王高君, 李洪利, 胡温庭, 孙学辉. miR-485-5p靶向RAPTOR影响口腔鳞状细胞癌迁移、侵袭和增殖[J]. 口腔医学研究, 2024, 40(5): 429-435.
[5]	房敏健, 刘亮, 邱若兰, 曹伟, 葛素云, 柴大敏. 肿瘤间质比在口腔鳞状细胞癌患者预后评估中的价值分析[J]. 口腔医学研究, 2024, 40(3): 242-247.
[6]	李易玮, 孙雅楠, 潘军臣, 胡雅英, 张钰莹, 马纪源, 张佳莉. Barx2驱动口腔鳞状细胞癌肿瘤特异性MHC-Ⅱ类信号诱导CD4⁺T/CD8⁺T细胞活化[J]. 口腔医学研究, 2023, 39(8): 684-689.
[7]	陈卓晅, 陈林林. 早期口腔鳞状细胞癌浸润深度检查方法的研究进展[J]. 口腔医学研究, 2023, 39(6): 487-490.
[8]	杨可, 孙雅楠, 胡雅英, 吕宜楠, 郑小风, 李易玮, 张佳莉. cyclin D1表达模式深度学习识别和预测模型对HPV阴性口腔鳞状细胞癌和口咽鳞状细胞癌患者预后的预测作用[J]. 口腔医学研究, 2023, 39(4): 308-315.
[9]	王韧, 周诗洁, 郭锦材. 基于Clinicaltrials.gov平台的口腔鳞状细胞癌临床研究注册特点分析[J]. 口腔医学研究, 2023, 39(12): 1080-1084.
[10]	牛燕红, 夏成万, 章茜, 马冠宇, 王育新, 胡勤刚, 蒲玉梅. 超声加速卢戈氏碘液增强Micro-CT成像用于口腔鳞状细胞癌术中成像的可行性研究[J]. 口腔医学研究, 2023, 39(11): 982-987.
[11]	吴天赐, 郁佳鑫, 黄晓峰, 陈盛, 王育新, 蒲玉梅. 深度学习图片分类模型ResNet-18用于判定口腔鳞状细胞癌浸润方式的初步研究[J]. 口腔医学研究, 2023, 39(10): 917-922.
[12]	蒋志敏, 马国武, 孙波. Nomogram预测根治性切除局部晚期口腔鳞状细胞癌患者的预后[J]. 口腔医学研究, 2023, 39(1): 56-61.
[13]	吕宜楠, 胡雅英, 郑小风, 杨可, 张佳莉. IL-12A和EBI3在OSCC中的表达及其与免疫微环境的关系[J]. 口腔医学研究, 2022, 38(6): 533-539.
[14]	彭艳霜, 刘英. Sox基因在口腔鳞状细胞癌中作用及机制的研究进展[J]. 口腔医学研究, 2022, 38(4): 312-315.
[15]	胡勤刚, 泥艳红, 王雨晗. 代谢组学在口腔鳞状细胞癌早期诊断及精准诊疗中的研究进展[J]. 口腔医学研究, 2022, 38(3): 207-211.